41 reports
- SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
- SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
- Pharmaceutical Market, Chemical Company of Malaysia, Global, Major Products, 2016
- Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...
ANNOUNCED THAT ANTI-INFLUENZA DRUG CANDIDATES UNDER ITS FLUCIDE PROGRAM, WHEN GIVEN ORALLY, LED TO STRONG ANTIVIRAL ANTIBODY RESPONSE.
- Daiichi Sankyo Company Ltd - History
In May, Daiichi Sankyo Company, Limited entered into a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute for its influenza HA vaccine " Kaketsuken" .
- 9.3 BIBLIOGRAPHY
Clinical implications of antiviral resistance in influenza.
Influenzavirus B Infections - Pipeline Review, H1 2017
- LANINAMIVIR - DRUG PROFILE
It enables AMRI to develop and manufacture the influenza antiviral products.
Influenzavirus B Infections - Pipeline Review, H2 2017
- LANINAMIVIR - DRUG PROFILE
It enables AMRI to develop and manufacture the influenza antiviral products.
- Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...
Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.
Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016
- Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...
Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.
- SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 - 2017
- VALUE US$M
- DRUG PRODUCT
Opportunity Analyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024
- RESPIRATORY SYNCYTIAL VIRUS (RSV) - OPPORTUNITY ANALYSIS AND FORECASTS TO 2024
" [Adamantane] influenza antivirals had resistance develop very quickly on therapy...
- PARTNERSHIP - DEAL REPORTS
- PARTNERSHIP - DEAL REPORTS
a US-based contract research and manufacturing organization, has signed an agreement with Biota Holdings Limited, to further develop and manufacture Biota' s influenza antiviral CS## (laninamivir), a second-generation, long-acting neuraminidase inhibitor.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016
- SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
H3N2 Infection - Pipeline Review, H1 2016
- FEATURED NEWS & PRESS RELEASES
Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.
H1N1 Infection - Pipeline Review, H1 2016
- H1N1 Infection - Product Development Milestones
As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.
Biota Holdings Limited – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
- PARTNERSHIP - DEAL REPORTS
- DEAL REPORT: BIOTA SCIENTIFIC RECEIVES BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY...
Diabetic Foot Ulcers - Pipeline Review, H1 2017
- NAS-911 - DRUG PROFILE
In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.
Pandemic Influenza Global Clinical Trials Review, H1, 2016
- Clinical Trial Profile Snapshots
PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE EFFECTIVENESS (EAVE) - USE OF A UNIQUE COMMUNITY AND LABORATORY NATIONAL LINKED DATASET: AN OBSERVATIONAL LONGITUDINAL COHORT STUDY WITH NESTED-CASE CONTROL STUDY EARLY ESTIMATION OF PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE
Pandemic Influenza Global Clinical Trials Review, H2, 2015
- Clinical Trial Profile Snapshots
Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Prominent Drugs Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Pandemic Influenza Therapeutics Clinical Tr
H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015
- SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017
- 10.2. DEALS BY PRECLINICAL STAGE
antiviral vaccines Collaborative R& D agreement for AVE ## safety and tolerability Licensing agreement for tkRNAi technology Grant award for Parkinson' s disease research Yes Apr 2012 BioVest, US Army Medical Research Institute of Infectious Diseases Sanofi, Michael J Fox Foundatio
H3N2 Infection - Pipeline Review, H2 2015
- H3N2 Infection - Product Development Milestones
Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.
Seasonal Influenza - Pipeline Review, H2 2015
- Drug Profiles
VH-## elicits antiviral effects.
H1N1 Infection - Pipeline Review, H2 2015
- H1N1 Infection - Product Development Milestones
As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.
- LANINAMIVIR - DRUG PROFILE
IT ENABLES AMRI TO DEVELOP AND MANUFACTURE THE INFLUENZA ANTIVIRAL PRODUCTS.
- Influenza antivirals
- Description
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016
- NAS-911 - DRUG PROFILE
New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS## as a co-therapeutic for existing influenza antivirals currently available to flu patients.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2017
- NAS-911 - DRUG PROFILE
In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017
- NAS-911 - DRUG PROFILE
IN JULY 2014, NEW AMSTERDAM SCIENCES (NAS) ANNOUNCED THE COMPLETION OF INITIAL CONFIRMATORY STUDIES IN ANIMAL MODELS DESIGNATING OSELTAMIVIR (TAMIFLU) AND NAS LEAD COMPOUND NAS-## AS A CO-THERAPEUTIC FOR EXISTING INFLUENZA ANTIVIRALS CURRENTLY AVAILABLE TO FLU PATIENTS.